Sign in
TerminatedNo phase

Exploratory Metabolomics Study of Exhaled Breath in Pulmonary Embolism

Key facts

Who runs it
University Hospital, Strasbourg, France
Where
France1 site in 1 countryChoose a country to see its sites
Trial code
Status
Terminated
People taking part
1 person enrolled
Started
1 Dec 2021
Ended
15 Jan 2024
Type of study
Observational, 2 groups
Treatments tested
  • Pulmonary embolism diagnosis by nuclear medicine imaging
Record updated
29 August 2024
Why it stopped
recruitment difficulties

Who can take part

Age
18 years and older
Sex
Women and men

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • Male or female, at least 18 years old
  • Patients with clinical suspected pulmonary embolism
  • Patient willing and able to provide informed consent

Who cannot take part

  • Diagnosis of pulmonary embolism established prior to inclusion in the study
  • Contraindications to pulmonary ventilator-perfusion tomoscintigraphy
  • All types of thrombolytic or anticoagulant treatment
  • Massive pulmonary embolism (systolic pressure < 90 mm Hg)
  • Pregnancy
  • Breastfeeding

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Pulmonary embolism is a frequent and recurrent pathology, especially in the elderly. It is often preventable, with high mortality and morbidity, making it a major public health issue. The clinical presentation of pulmonary embolism is non-specific and very highly variable, ranging from asymptomatic thrombus diagnosed incidentally to sudden death. The current diagnosis of pulmonary embolism is based on several diagnostic techniques, mainly non-invasive, which should be used sequentially.

Read full original descriptionShow less

We propose to sample the volatile organic compounds using a device that allows them to be trapped on polymer cartridges. Sampling will be performed under monitoring of respiratory pressure and a capnograph to collect alveolar and upper respiratory tract air separately without contamination of the oral cavity or sinuses.

This exploratory metabolic analysis will be non-targeted (analysis of all molecules detectable without a priori).

The main objective of the study is to identify specific metabolic profiles to predict the results of ventilation-perfusion pulmonary tomoscintigraphy in subjects undergoing this examination for suspected acute pulmonary embolism.

Secondary purposes :

* To identify metabolic profiles to be used to predict, in combination with clinical probability scores, the results of ventilation-perfusion pulmonary tomoscintigraphy in subjects undergoing this examination for suspected acute pulmonary embolism.; * To correlate metabolic profiles with the topography of embolized lung territories

The 2 groups in the trial

  • Presence of pulmonary embolism

    ≥ 1 noninfused and normoventilated segment(s) by pulmonary tomoscintigraphy

    Treatment: Pulmonary embolism diagnosis by nuclear medicine imaging

  • No pulmonary embolism

    Pulmonary perfusion without anomaly (segmental or sub-segmental) by pulmonary tomoscintigraphy

    Treatment: Pulmonary embolism diagnosis by nuclear medicine imaging

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
29 August 2024